Clinical Trials - October 27, 2021
Ultimovacs to launch Phase II combination trial
Ultimovacs’s universal cancer vaccine, UV1, will be investigated in a new Phase II clinical trial in combination with pembrolizumab in non-small cell lung cancer (NSCLC). The first patient is expected to be treated in H1 2022, with data read-out from the trial, LUNGVAC, anticipated by the end of 2024. “We see this new trial as […]
Biotech Business - October 22, 2021
Ultimovacs receives dual FDA Fast Track designation
Ultimovacs has announced that its universal cancer vaccine, UV1, in combination with checkpoint inhibitors has received Fast Track designation from the U.S. FDA in the treatment of unresectable or metastatic melanoma – either as add-on therapy to pembrolizumab or as add-on therapy to ipilimumab. Ultimovacs is currently evaluating UV1 as add-on therapy to ipilimumab and […]
Clinical Trials - October 18, 2021
Ultimovacs announces positive follow-up data
Ultimovacs has announced continuing positive topline results in its ongoing US-based Phase I clinical trial evaluating the company’s universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab as a first-line treatment in metastatic malignant melanoma. The trial had previously reached its primary endpoint of safety and tolerability and at 24 months of follow-up […]
Clinical Trials - October 4, 2021
Ultimovacs begins dosing of 2nd cohort in Phase I TENDU study
Ultimovacs has started dosing of the second cohort in the Phase I TENDU trial, evaluating the company’s Tetanus-Epitope Targeting (TET)-platform. The TENDU clinical trial, conducted at the Oslo University Hospital, is a first-in-human, dose-escalation study designed to generate initial safety and immune activation data for a prostate cancer-specific therapeutic TET-based vaccine in prostate cancer patients […]
Pharma article - September 17, 2021
Interview: Jens Bjørheim, Chief Medical Officer, Ultimovacs
The company’s universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab, has recently demonstrated a 60% objective response rate in metastatic malignant melanoma. Nordic Life Science asked the Chief Medical Officer (CMO) of Ultimovacs, Jens Bjørheim, about the new findings and the company’s further development of UV1. Describe your reactions to these new, […]
Clinical Trials - August 12, 2021
Further positive trial results from Ultimovacs
Ultimovacs has announced positive results from the second cohort of 10 patients after one year of its ongoing US-based Phase I clinical trial. The clinical trial evaluates the company’s universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab as a first-line treatment in metastatic malignant melanoma. “These latest results are compelling, and in […]
